Merck & Co., Inc. (TSX:MRK)
32.32
-0.87 (-2.62%)
Sep 30, 2026, 3:50 PM EST
Merck & Co. Employees
As of December 31, 2025, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees did not change compared to the previous year.
Employees
75,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
1.28M CAD
Profits / Employee
60.89K CAD
Market Cap
508.95B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 75,000 | 0 | - | 73,000 | 2,000 |
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% | 73,000 | 2,000 |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% | 70,000 | 2,000 |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% | 67,000 | 2,000 |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% | 67,000 | 1,000 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Merck & Co. News
- 15 hours ago - Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright - TheFly
- 17 hours ago - Merck says experimental skin disease drug meets main goal in mid-stage study - Reuters
- 17 hours ago - Merck says tulisokibart met primary, secondary endpoints in Phase 2b study - TheFly
- 17 hours ago - Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) - Business Wire
- 1 day ago - Merck price target raised to $180 from $155 at Scotiabank - TheFly
- 2 days ago - US drugmakers turn to China for licensing deals - Reuters
- 2 days ago - Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
- 2 days ago - Merck enters global license agreement with SciBrunch Therapeutics for SPR2015 - TheFly